FindTrial
Sign In

Optimized treatment plan for integrated traditional Chinese and western medicine intervention for HBV-related primary liver cancer in the middle and advanced stages of standard treatment of case prospective, controlled, Real-World cohort study

A prospective, controlled, Real-World cohort study to evaluate the overall survival and progression-free survival of HBV-related primary liver cancer in the middle and late stages of the standard treatment of the optimized regimen of integrated traditional Chinese and western medicine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005552
Enrollment
Unknown
Registered
2022-01-22
Start date
2020-06-09
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Control group:Standardized Treatment
therapy group:Heshuxiaoji Pill + Standardized Treatment

Sponsors

The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ?Meet the diagnostic criteria of chronic hepatitis B; ?Meet the diagnostic criteria of primary liver cancer; ?Barcelona stage B-D, can accept standardized treatment procedures; ?age =18 years old, =75 years old; ?sign informed consent.

Exclusion criteria

Exclusion criteria: ?Patients with severe acute and chronic diseases, including myocardial infarction, stroke, heart failure, uncontrolled diabetes and HIV, etc.; ?Co-infection with other viral hepatitis, severe alcoholic liver disease, autoimmune liver disease, severe fatty liver disease, etc. Patients with other liver diseases; ?A history of drug abuse or mental illness; ?Received other research or anti-tumor drugs in the past 4 weeks; ?Pregnant or lactating women.

Design outcomes

Secondary

MeasureTime frame
Liver function classification;Evaluation of solid tumors (m-recist criteria);HBV DNA;chest CT;TCM symptom score;Quality of life score;AFP;—

Primary

MeasureTime frame
Progression-free survival;Overall survival;Overall survival;—

Countries

China

Contacts

Public ContactWang Jing

The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University

lywj68@126.com18011026162

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026